Cardiovascular safety study of Magnevist® Injection at two dose levels and two injection rates in normal subjects
The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine) injection has on the way the heart conducts the electrical impulses that allow it to beat effectively. The study will compare Magnevist injection's effect to that of placebo (a saline injection).
- Subjects with an electrocardiogram [ECG] (normal sinus rhythm [SR], QTc > 450 msec) without clinically significant abnormalities - Non-smoker
- History of cardiovascular disease- Pregnant or nursing- Had any contraindication to moxifloxacin
Miami, United States, 33181-3405
E-mail: [email protected]
Phone: Not Available
Cardiovascular safety study of 0.1 and 0.3 mmol/kg Magnevist® Injection at two injection rates (bolus and 10 mL/15 sec.) in normal subjects following a randomized, cross-over design using placebo and a concurrent positive control